Coverage / GILD / Trade Card

GILD

Gilead Sciences, Inc

OPPORTUNISTIC BUY 2026-08-08 Data 35 days old USD 133.21 Healthcare - Drug Manufacturers - GeneralAWAIT ENTRY
ACTIONABLEMethodology gates passed
62

Position levels

Currenttoday
USD 133.21
Buy <=wait / entry
USD 118.33
Trim >=take some off
USD 145.00
Thesis breakConfirmation of accelerated generic erosion of Biktarvy or another core HIV asse...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case30%100 / 10030.0
Base case49%62 / 10030.4
Bear case21%10 / 1002.1
Weighted conviction62 / 100 - OPPORTUNISTIC BUY

Top risks

  • Earnings beat of $0.51 vs consensus with 10.6% revenue growth
  • Raised 2026 base-business sales outlook to $29.8B - $30.1B and HIV growth forecast to 9% - 10%
  • HIV sales +12% with PrEP revenue exceeding $1B and Trodelvy sales +26%
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.